QT
ADMS

Quantamental Technologies’s Adamas Pharmaceuticals ADMS Stock Holding History

Quantamental Technologies’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,101
Closed -$26K – 1548
2019
Q3 		$26K Buy
5,101
+1,000
+24% +$6.17K 0.01% 1156
2019
Q2 		$25K Buy
+4,101
New +$23.6K 0.01% 1093
2019
Q1 		– Sell
-200
Closed -$2K – 1892
2018
Q4 		$2K Buy
+200
New +$2.6K ﹤0.01% 1287

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Quantamental Technologies's ADMS Position: Q4 2019 in Review

Quantamental Technologies sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 5,101 shares — an estimated $26K sold.

Quantamental Technologies first reported a position in ADMS in Q4 2018 and held it in 3 quarters. The position peaked at $26K in Q3 2019. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Quantamental Technologies reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 5,101 Adamas Pharmaceuticals shares in Q4 2019, an estimated $26K.
  • Quantamental Technologies first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Quantamental Technologies's Adamas Pharmaceuticals position peaked at $26K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.